COST-UTILITY ANALYSIS OF TERIFLUNOMIDE IN NAIVE VS. PREVIOUSLY TREATED PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

被引：0
|
作者：
Lazzaro, C. [1 ]
Bergamaschi, R. [2 ]
Zaffaroni, M. [3 ]
Totaro, R. [4 ]
Paolicelli, D. [5 ]
机构：
[1] Studio Econ Sanit, Milan, MI, Italy
[2] IRCCS Mondino Fdn, Pavia, Italy
[3] Hosp Gallarate, ASST Valle Olona, Multiple Sclerosis Ctr, Gallarate, Italy
[4] Osped San Salvatore, Ctr Malattie Demielinizzanti, Laquila, Italy
[5] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND45
引用
收藏
页码：S631 / S631
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF DIMETHYL-FUMARATE COMPARED TO TERIFLUNOMIDE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Santoni, L.
    Prosperini, L.
    Cardillo, A.
    VALUE IN HEALTH, 2020, 23 : S630 - S630
  • [42] COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Puma, E.
    Santoni, L.
    Prosperini, L.
    VALUE IN HEALTH, 2019, 22 : S740 - S741
  • [43] Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
    Roos, Izanne
    Hughes, Stella
    McDonnell, Gavin
    Malpas, Charles B.
    Sharmin, Sifat
    Boz, Cavit
    Alroughani, Raed
    Ozakbas, Serkan
    Buzzard, Katherine
    Skibina, Olga
    van der Walt, Anneke
    Butzkueven, Helmut
    Lechner-Scott, Jeannette
    Kuhle, Jens
    Terzi, Murat
    Laureys, Guy
    Van Hijfte, Liesbeth
    John, Nevin
    Grammond, Pierre
    Grand'Maison, Francois
    Soysal, Aysun
    Jensen, Ana Voldsgaard
    Rasmussen, Peter Vestergaard
    Svendsen, Kristina Bacher
    Barzinji, Ismael
    Nielsen, Helle Hvilsted
    Sejbaek, Tobias
    Prakash, Sivagini
    Stilund, Morten Leif Munding
    Weglewski, Arkadiusz
    Issa, Nadia Mubder
    Kant, Matthias
    Sellebjerg, Finn
    Gray, Orla
    Magyari, Melinda
    Kalincik, Tomas
    MSBase Study Grp
    Danish MS Registry Study Grp
    JAMA NEUROLOGY, 2023, 80 (08) : 789 - 797
  • [44] Matters arising: cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review
    Lazzaro, Carlo
    Bergamaschi, Roberto
    Zaffaroni, Mauro
    Totaro, Rocco
    Paolicelli, Damiano
    HEALTH ECONOMICS REVIEW, 2025, 15 (01):
  • [45] Teriflunomide improves quality of life in a Greek cohort of relapsing-remitting multiple sclerosis patients switched from injectables: Subgroup analysis of previously-treated patients in the AURELIO study
    Dardiotis, E.
    Perpati, G.
    Borsos, M.
    Nikolaidis, I.
    Tzanetakos, D.
    Koutlas, E.
    Kilidireas, C.
    Mitsikostas, D. D.
    Hadjigeorgiou, G.
    Grigoriadis, N.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 702 - 703
  • [46] Neurocognitive changes in patients with relapsing-remitting multiple sclerosis treated with natalizumab
    Doehler, N.
    Mueller, S.
    Vehoff, J.
    Galovic, M.
    Tettenborn, B.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 213
  • [47] Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
    Marita Zimmermann
    Elizabeth Brouwer
    Jeffrey A. Tice
    Matt Seidner
    Anne M. Loos
    Shanshan Liu
    Richard H. Chapman
    Varun Kumar
    Josh J. Carlson
    CNS Drugs, 2018, 32 : 1145 - 1157
  • [48] BELGIAN COST-UTILITY ANALYSIS OF GILENYA® (FINGOLIMOD) IN THE MANAGEMENT OF ADULTS WITH ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS
    Drieskens, S.
    Moeremans, K.
    VALUE IN HEALTH, 2011, 14 (07) : A323 - A323
  • [49] Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis
    Crespo, C.
    Izquierdo, G.
    Garcia-Ruiz, A.
    Granell, M.
    Brosa, M.
    NEUROLOGIA, 2014, 29 (04): : 210 - 217
  • [50] Glatiramer acetate in treatment-naive and immunomodulatory pre-treated relapsing-remitting multiple sclerosis patients
    Baumhackl, Ulf
    Pantev, Marina
    Klasser, Manfred
    MULTIPLE SCLEROSIS, 2008, 14 : S31 - S31
12345